The Effect of Prednisone on Atherogenesis as Studied in the Macrophage Foam Cell Formation Model System.

Plain-language summary

This study examined the effect of the drug Prednisone on the formation of macrophage foam cells, which play a role in the development of atherosclerosis (atherogenesis), in healthy male volunteers. It enrolled healthy men aged 18 to 50 with no history of illness. The trial was conducted in Early Phase 1 and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Early Phase 1

Status

Completed

Sponsor

Prof. Tony hayek MD

Intervention

Prednisone 20 Mg, Prednisone 40 Mg

Start date

1/17/2018

Estimated completion

9/30/2018

Countries

Israel

Related genes

Locations

• Haifa, Israel

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Male subjects between the ages of 18-50 years of age, with a body mass index within the range of 18 to 27 kg/m2, with no previous medical history of illnesses or drug allergy and with no current medical treatments.

Exclusion Criteria:

* Students or hospital employees under the direct supervision of the PI or lead researcher. Any previous history of acute or chronic illnesses including but not limited to Cardiovascular, Pulmonary, Gastrointestinal, Renal, Endocrinal, Cancer, Diabetes or Pre-Diabetes (HbA1c \> 5.5%), Hypertension, Dyslipidemia, Smoking, or who had taken glucocorticoids within the previous 3 months before the study.